Aldeyra Therapeutics (NASDAQ:ALDX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.14), Fidelity Earnings reports.
ALDX traded up $0.17 during midday trading on Friday, hitting $5.93. The company’s stock had a trading volume of 163,800 shares, compared to its average volume of 350,763. The firm has a 50-day moving average price of $5.67 and a two-hundred day moving average price of $6.08. Aldeyra Therapeutics has a 52-week low of $4.31 and a 52-week high of $12.79. The firm has a market cap of $167.68 million, a P/E ratio of -3.31 and a beta of 0.84.
A number of research firms recently commented on ALDX. ValuEngine upgraded Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $33.00 price objective on shares of Aldeyra Therapeutics in a research report on Thursday, October 17th. Finally, Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $24.19.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Further Reading: Capital Gains Distribution
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.